Figure 1 | Scientific Reports

Figure 1

From: Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen

Figure 1

Combination Index for Tamoxifen and Alpelisib in Different ER-Positive Breast Cancer Cell Lines. (A) MCF-7 (PIK3CA mutation), (B) T47D (PIK3CA mutation), (C) ZR75-1 (PIK3CA wild type, PTEN loss), (D) HCC1500 (PIK3CA wild type, PTEN intact) and (E) Calculated combination index. These ER-positive breast cancer cells were treated with tamoxifen and alpelisib at different concentrations for 6 days. Combination indices were calculated to determine the relationship between drug synergism and genetic alterations in the PI3K pathway.

Back to article page